Pilot study of azithromycin for treatment of primary and secondary syphilis

Clinical Infectious Diseases

Volumn 19, Issue 3, 1994, Pages 486-488

  Verdon, Michael S ^a,b   Handsfield, H Hunter ^a,b   Johnson, Raymond B ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CONTROL; DOSE RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION; RELAPSE; SYPHILIS; TREPONEMA PALLIDUM; VOMITING;

ADMINISTRATION, ORAL; ADULT; AZITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; PILOT PROJECTS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SYPHILIS; TREATMENT OUTCOME;

EID: 0028070970     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/19.3.486     Document Type: Article

References (10)

1. Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep 1993;42(RR-14):30-2.
2. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44:750-99.
3. Davila D, Kolacny-Babic L, Plavsic F. Pharmacokinetics of azithromycin after single oral dosing of experimental animals. Biopharm Drug Dispos 1991;12:505-14.
4. Stamm LV, Parrish EA. In-vitro activity of azithromycin and CP-63, 956 against Treponema pallidum. J Antimicrob Chemother 1990;25(suppl A): 11-4.
5. Lukehart SA, Fohn MJ, Baker-Zander SA. Efficacy of azithromycin fortherapy of active syphilis in the rabbit model. J Antimicrob Chemother 1990;25(suppl A):9l-9.
6. Gladue RP, Bright GM, Isaacson RE. Newborg MF. In vitro and in vivouptake of azithromycin (CP-62.993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
7. Girard AE, Girard D, English AR, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62, 993), a new macrolide with an extended half-life and excellent tissue distribution, Antimicrob Agents Chemother 1987;31:1948-54.
8. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992;327:921-5.
9. Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994;21:107-11.
10. Stamm WE, Workowski K, Hicks CB, et al. Azithromycin in the treatment of nongonococcal urethritis: a multicenter, double-blind, double-dummy study employing doxycycline as a comparative agent [abstract 10]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993.